Previous 10 |
home / stock / mdclf / mdclf news
MedinCell (OTCPK:MDCLF): 1H GAAP EPS of -€0.47. Revenue of €4.08M (+29.5% Y/Y) Press Release As of September 30, 2021, MedinCell had €34.4M in cash and €3.0M in non-risky financial assets, compared to €47.1M in cash and €3.9M in non-risky financi...
Teva Pharmaceutical (NYSE:TEVA) is scheduled to announce Q3 earnings results on Wednesday, October 27th, before market open. The consensus EPS Estimate is $0.65 (+12.1% Y/Y) and the consensus Revenue Estimate is $4.05B (+1.3% Y/Y). Over the last 2 years, TEVA has beaten EPS estimates 75% of t...
MedinCell S.A. (MDCLF): FY net loss of €19.02MRevenue of €8.2M (+187.7% Y/Y)Press Release For further details see: MedinCell S.A. reports FY results
Teva Pharmaceuticals (TEVA) and MedinCell (MDCLF) announce positive results for study TV46000-CNS-30072 (the RISE study), a Phase 3 clinical trial designed to evaluate the efficacy of TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) as a treatment for...
News, Short Squeeze, Breakout and More Instantly...
Medical Intelligence Technologies Inc Company Name:
MDCLF Stock Symbol:
OTCMKTS Market:
Medincell will receive an upfront payment of $35 million and is eligible for up to $1.9 billion in potential development and commercial milestones, plus royalties on worldwide sales. Medincell and AbbVie will co-develop, and AbbVie will commercialize up to six cutting-edge long-acting inj...
Global health agency Unitaid has awarded Medincell (Paris:MEDCL) an extension grant of up to US$ 6 million over three years to fund the clinical phase 1 activities of long-acting injectable mdc-STM. If proven safe, effective, and acceptable, mdc-STM could have a significant impact on transmission...
Guidance for 2024 UZEDY Teva’s revenue: ~ $80 million Olanzapine LAI ongoing Phase 3: 675 patients (recruitment completed), 62% of the targeted 3,600 injections performed, no PDSS (Post injection Delirium/Sedation Syndrome) observed MedinCell (Paris:MEDCL): Access...